Guggenheim Downgrades enGene Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 89.1%

Neg 89.1% Neu 0% Pos 0%

Guggenheim analyst Michael Schmidt downgrades enGene Therapeutics (NASDAQ:ENGN) from Buy to Neutral.

Comments

No comments yet. Be the first!